Manufacturer of Pralsetinib

Pralsetinib (Pralsetinib) was originally developed and produced by Blueprint Medicines. The U.S. Food and Drug Administration (FDA) has approved platinib for the treatment of adult patients with metastatic rearrangement during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

The approval is based on data from the Phase 1/2 ARROW clinical trial, which demonstrated the efficacy of platinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatment, and regardless of RET fusion partner or central nervous system involvement. Platinib, a once-daily oral RET-targeted therapy developed by Blueprint Medicines, is designed to selectively and potently inhibit the RET alterations that drive many cancer types, including approximately 1% to 2% of patients with non-small cell lung cancer. Currently, RET is one of seven non-small cell lung cancer biomarkers that can be targeted by FDA-approved treatments.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.